menu
    • menu
    [{"orgOrder":0,"company":"Leyden Labs","sponsor":"Nanopharm","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Undisclosed","year":"2021","type":"Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Preclinical","graph3":"Leyden Labs","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Spray","sponsorNew":"Leyden Labs \/ Nanopharm","highestDevelopmentStatusID":"4","companyTruncated":"Leyden Labs \/ Nanopharm"},{"orgOrder":0,"company":"Leyden Labs","sponsor":"European Innovation Council","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"NETHERLANDS","productType":"Antibody, Unconjugated","year":"2025","type":"Financing","leadProduct":"CR9114","moa":"Hemagglutinin","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Leyden Labs","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0.029999999999999999,"dosageForm":"Spray","sponsorNew":"Leyden Labs \/ European Innovation Council","highestDevelopmentStatusID":"6","companyTruncated":"Leyden Labs \/ European Innovation Council"}]

    Find Clinical Drug Pipeline Developments & Deals by Leyden Labs

    Menu

    Leyden Labs

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Leyden Labs

                            Netherlands arrow
                            AES
                            Not Confirmed

                            Leyden Labs

                            Netherlands arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : CR9114

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : European Innovation Council

                            Deal Size : $34.9 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Leyden Labs Secures €30M to Advance Nasal Spray for Respiratory Viruses

                            Details : The Series B financing for CR9114, an unconjugated antibody targeting influenza, aims to advance research in the field.

                            Product Name : CR9114

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Undisclosed

                            October 02, 2025

                            Lead Product(s) : CR9114

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : European Innovation Council

                            Deal Size : $34.9 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Leyden Labs

                            Netherlands arrow
                            AES
                            Not Confirmed

                            Leyden Labs

                            Netherlands arrow
                            AES
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Preclinical

                            Sponsor : Nanopharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Nanopharm and Leyden Labs Ink Deal to Develop Intranasal Spray Product for Prophylactic Use Against Known and ...

                            Details : Nanopharm will screen and subsequently develop a liquid nasal spray formulation, including performance testing and nasal deposition studies, to prepare Leyden Labs for Phase 1 clinical studies.

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            July 21, 2021

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Preclinical

                            Sponsor : Nanopharm

                            Deal Size : Undisclosed

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth